LSA
ATNM icon

Leonteq Securities AG’s Actinium Pharmaceuticals ATNM Stock Holding History

Leonteq Securities AG’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$3.69K – 1205
2024
Q2 		$3.69K Hold
500
– – ﹤0.01% 1070
2024
Q1 		$3.9K Buy
+500
New +$3.21K ﹤0.01% 1103
2022
Q4 		– Sell
-12,000
Closed -$89.3K – 1295
2022
Q3 		$89.3K Buy
12,000
+4,000
+50% +$24.9K ﹤0.01% 671
2022
Q2 		$39.5K Buy
+8,000
New +$45.4K ﹤0.01% 877

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Leonteq Securities AG's ATNM Position: Q3 2024 in Review

Leonteq Securities AG sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 500 shares — an estimated $3.69K sold.

Leonteq Securities AG first reported a position in ATNM in Q2 2022 and held it in 4 quarters. The position peaked at $89.3K in Q3 2022. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • Leonteq Securities AG reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Leonteq Securities AG sold 500 Actinium Pharmaceuticals shares in Q3 2024, an estimated $3.69K.
  • Leonteq Securities AG first reported a position in Actinium Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Leonteq Securities AG's Actinium Pharmaceuticals position peaked at $89.3K in Q3 2022.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on Leonteq Securities AG's 13F filing for Q3 2024, filed 4 Mar 2026.